Research programme: colloidal gold-based cancer therapeutics - CytImmune Sciences

Drug Profile

Research programme: colloidal gold-based cancer therapeutics - CytImmune Sciences

Alternative Names: AuriCin; AuriTax; AuriTol; CYT-20000; CYT-21000; CYT-21001; CYT-21304; CYT-31000; CYT-41000; CYT-51000; CYT-61000; CYT-71000; PT-cAu-TNF

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytImmune Sciences
  • Class Metals; Paclitaxels; Polyethylene glycols; Tumour necrosis factors
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Injection)
  • 27 Feb 2013 OctoPlus has been acquired by Dr Reddys Laboratories
  • 16 Apr 2008 Pharmacodynamics data from a preclinical trial presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top